Distinct ERG Rearrangement Prevalence in Prostate Cancer: Higher Frequency in Young Age and in Low PSA Prostate Cancer

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2013 Feb 6

PMID 23381693

Citations 36

Authors

G Schaefer

J-M Mosquera

R Ramoner

K Park

A Romanel

E Steiner

W Horninger

J Bektic

M Ladurner-Rennau

M A Rubin

F Demichelis

H Klocker

Affiliations

Soon will be listed here.

Abstract

Background: The TMPRSS2-ERG gene fusion resulting in ERG overexpression has been found in around 50% of prostate cancers (PCa) and is a very early event in tumorigenesis. Most studies have reported on selected surgical cohorts with inconsistent results. We hypothesized that ERG gene rearrangements impact tumor development and investigated the frequency of ERG overexpression in the context of clinicopathological tumor characteristics.

Methods: ERG overexpression (ERG+ or ERG-) was determined by immunohistochemistry (IHC) in 1039 radical prostatectomy (RP) tumors and association with PSA, D'Amico risk score, histopathology, biochemical recurrence, body mass index and age of PCa cases was analyzed.

Results: ERG+ was associated with younger age at diagnosis (P<0.0001), lower serum PSA (P=0.002) and lower prostate volume (PV) (P=0.001). It was most frequent in the youngest age quartile (≤55 years, 63.9% ERG+) and decreased constantly with increasing age to 40.8% in the oldest age quartile (≥67 years, P<0.0001). In the PSA range <4 ng ml(-1) the frequency of ERG positivity was 60.2% compared with 47.5 and 49.1% in the PSA ranges 4-10 and ≥10 ng ml(-1), respectively. In the first age quartile, ERG+ patients had lower median serum PSA and fPSA% and smaller PV. In the highest age quartile tumor volume (TV) was increased. Similar differences were observed in the low PSA range. Multivariate analysis identified the first age quartile as a predictor for ERG status (odds ratios (OR) 2.05, P=0.007). No association was found with the D'Amico progression risk score and with biochemical tumor recurrence.

Conclusions: ERG+ tumors manifest clinically at lower PSA levels and their prevalence is age dependent. This suggests acceleration of tumor development by ERG overexpression that results in earlier tumor detection in young patients. Long-term results are warranted to determine the impact of ERG overexpression on disease outcome.

Citing Articles

Germline determinants of aberrant signaling pathways in cancer.

Dalfovo D, Scandino R, Paoli M, Valentini S, Romanel A NPJ Precis Oncol. 2024; 8(1):57.

PMID: 38429380 PMC: 10907629. DOI: 10.1038/s41698-024-00546-5.

Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.

Segales L, Juanpere N, Gallarin N, Lorenzo M, Lopez D, Perera-Bel J Virchows Arch. 2023; 485(2):281-290.

PMID: 38017230 PMC: 11329545. DOI: 10.1007/s00428-023-03699-z.

Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.

Acosta-Vega N, Varela R, Mesa J, Garai J, Baddoo M, Gomez-Gutierrez A Cancer Med. 2022; 12(4):4306-4320.

PMID: 36329628 PMC: 9972164. DOI: 10.1002/cam4.5301.

The evolving landscape of prostate cancer somatic mutations.

Cotter K, Rubin M Prostate. 2022; 82 Suppl 1:S13-S24.

PMID: 35657155 PMC: 9328313. DOI: 10.1002/pros.24353.

Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.

Han H, Lee H, Choi K, Moon Y, Heo J, Ham W Prostate Cancer Prostatic Dis. 2021; 24(4):1080-1092.

PMID: 33903734 PMC: 8616761. DOI: 10.1038/s41391-021-00364-x.

References

Casey O, Fang L, Hynes P, Abou-Kheir W, Martin P, Tillman H . TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One. 2012; 7(7):e41668. PMC: 3408501. DOI: 10.1371/journal.pone.0041668. View

Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E . Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42. DOI: 10.1016/j.eururo.2012.11.014. View

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R . TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2010; 71(5):489-97. DOI: 10.1002/pros.21265. View

Tomlins S, Aubin S, Siddiqui J, Lonigro R, Sefton-Miller L, Miick S . Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011; 3(94):94ra72. PMC: 3245713. DOI: 10.1126/scitranslmed.3001970. View

Rickman D, Soong T, Moss B, Mosquera J, Dlabal J, Terry S . Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A. 2012; 109(23):9083-8. PMC: 3384175. DOI: 10.1073/pnas.1112570109. View

Chen Y, Sawyers C . Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell. 2010; 17(5):415-6. PMC: 2931314. DOI: 10.1016/j.ccr.2010.04.022. View

Perner S, Svensson M, Hossain R, Day J, Groskopf J, Slaughter R . ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology. 2009; 75(4):762-7. PMC: 2850965. DOI: 10.1016/j.urology.2009.10.010. View

Elmlinger M, Kuhnel W, Wormstall H, Doller P . Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab. 2005; 51(11-12):625-32. View

Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur S . TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26(31):4596-9. DOI: 10.1038/sj.onc.1210237. View

10.

Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A . The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-20. PMC: 3075885. DOI: 10.1038/nature09744. View

11.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R . TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011; 6(7):e21650. PMC: 3128608. DOI: 10.1371/journal.pone.0021650. View

12.

Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo M . Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol. 2010; 183(5):2054-61. DOI: 10.1016/j.juro.2009.12.096. View

13.

Wolters T, Roobol M, van Leeuwen P, van den Bergh R, Hoedemaeker R, van Leenders G . Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. Eur Urol. 2009; 57(5):821-9. DOI: 10.1016/j.eururo.2009.07.027. View

14.

Epstein J, Allsbrook Jr W, Amin M, Egevad L . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42. DOI: 10.1097/01.pas.0000173646.99337.b1. View

15.

Falzarano S, Zhou M, Hernandez A, Klein E, Rubin M, Magi-Galluzzi C . Single focus prostate cancer: pathological features and ERG fusion status. J Urol. 2010; 185(2):489-94. DOI: 10.1016/j.juro.2010.09.093. View

16.

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

17.

Pettersson A, Graff R, Bauer S, Pitt M, Lis R, Stack E . The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1497-509. PMC: 3671609. DOI: 10.1158/1055-9965.EPI-12-0042. View

18.

Mosquera J, Mehra R, Regan M, Perner S, Genega E, Bueti G . Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-11. PMC: 3717524. DOI: 10.1158/1078-0432.CCR-08-2927. View

19.

Park K, Tomlins S, Mudaliar K, Chiu Y, Esgueva R, Mehra R . Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7):590-8. PMC: 2907585. DOI: 10.1593/neo.10726. View

20.

Demichelis F, Setlur S, Banerjee S, Chakravarty D, Chen J, Chen C . Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A. 2012; 109(17):6686-91. PMC: 3340033. DOI: 10.1073/pnas.1117405109. View